Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml)
Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) is a medicine authorised by Swissmedic under authorisation number 68609. The authorisation holder is Bristol-Myers Squibb SA. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 23 December 2022 and the authorisation is limited until 22 December 2027. ATC code L01FY02 places the medicine in the group Antineoplastic agents.
| Authorisation number | 68609 |
|---|---|
| Name | Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) |
| Full name | Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer Infusionslösung |
| Authorisation holder | Bristol-Myers Squibb SA |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01FY02 |
| First authorisation | 23 December 2022 |
| Authorisation validity | 22 December 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer Infusionslösung | A | 23 December 2022 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Durchstechflasche(n) | L01FY02 | 07.16.1. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) authorised in Switzerland?
Yes. Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) is authorised by Swissmedic under authorisation number 68609, data as of 01 September 2026. The authorisation is limited until 22 December 2027.
Which dispensing category does Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) have?
Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml)?
The authorisation holder is Bristol-Myers Squibb SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.